机译:MiR-130A通过靶向TSC1来推动MTOR途径,并通过NF-Kappa B在高级浆液卵巢癌中转灭
Shandong Univ Dept Cell Biol Sch Med 44 Wenhuaxi Rd Jinan 250012 Shandong Peoples R China;
Shandong Univ Sch Med Dept Mol Med &
Genet Jinan 250012 Shandong Peoples R China;
Shandong Univ Sch Med Dept Pathogen Biol Jinan 250012 Shandong Peoples R China;
Chongqing Univ Sch life Sci Chongqing 401331 Peoples R China;
Shandong Univ Dept Cell Biol Sch Med 44 Wenhuaxi Rd Jinan 250012 Shandong Peoples R China;
Shandong Univ Qilu Hosp Dept Obstet &
Gynecol Jinan 250012 Shandong Peoples R China;
Shandong Univ Qilu Hosp Dept Obstet &
Gynecol Jinan 250012 Shandong Peoples R China;
Shandong Univ Dept Cell Biol Sch Med 44 Wenhuaxi Rd Jinan 250012 Shandong Peoples R China;
Shandong Univ Dept Cell Biol Sch Med 44 Wenhuaxi Rd Jinan 250012 Shandong Peoples R China;
Shandong Univ Dept Cell Biol Sch Med 44 Wenhuaxi Rd Jinan 250012 Shandong Peoples R China;
Shandong Univ Dept Cell Biol Sch Med 44 Wenhuaxi Rd Jinan 250012 Shandong Peoples R China;
Northwestern Univ Sch Med Dept Pathol Chicago IL 60611 USA;
Shandong Univ Sch Med Dept Mol Med &
Genet Jinan 250012 Shandong Peoples R China;
Shandong Univ Qilu Hosp Dept Obstet &
Gynecol Jinan 250012 Shandong Peoples R China;
Shandong Univ Dept Cell Biol Sch Med 44 Wenhuaxi Rd Jinan 250012 Shandong Peoples R China;
机译:MiR-130A通过靶向TSC1来推动MTOR途径,并通过NF-Kappa B在高级浆液卵巢癌中转灭
机译:除了P53和PTEN:鉴定高级别浆液性卵巢癌中RAS / MAPK和PI3K / AKT信号通路的分子改变,以确定潜在的新型治疗靶点
机译:除了P53和PTEN之外:鉴定高级浆液卵巢癌中RAS / MAPK和PI3K / AKT信号传导途径的分子改变,以确定潜在的新疗效目标
机译:卵巢高级浆液癌的全局蛋白质组学分析使用SWATH-MS进行靶向验证与基因组改变相关的蛋白质组变化
机译:SUSD2在高级浆液性卵巢癌进展中的抑制作用。
机译:miR-130a通过靶向TSC1上调mTOR途径并在高度浆液性卵巢癌中被NF-κB激活
机译:MEK1 / 2途径作为高级浆液卵巢癌的治疗靶标
机译:卵巢浆液性癌的发病机制是免疫定向诊断和治疗的基础。项目1 - 沿不同途径发展的卵巢浆液性肿瘤的分子特征